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Abstract
Background: Dual loading drug delivery system with tumor targeting efficacy and sequential release function
provides a promising platform for anticancer drug delivery. Herein, we established a novel AuCOOH@FACS nanogel
system for co-delivery miR-218 mimics (as bio-drug) and Temozolomide(as chemo-drug).
Methods: DLS and TEM were employed to determine the characteristics of particles and nanogels. The cell viability
was calculated for study synergistic effect of both drugs coadministration and in nanogel forms. The amounts of Au
uptake were measured by ICP-MS in cell and tumors to quantify the targeting drug delivery efficacy. Tumor weight
and mice weight were investigated to study the targeting antitumor efficacy of nanogel system.
Results: The results revealed that using AuCOOH@FACS nanogel as delivery vehicles, drugs could be targeting
delivery to tumor site, the intracellular uptake is enhanced to a greater extent, and significant antitumor efficacy is
fold increase compared with free drug administration group, without noticeable system cytotoxicity.
Conclusions: This system offers an efficient approach to cancer therapy and holds significant potential to improve
the treatment of cancer in the future.
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Introduction
Nanoscaled drug carriers have been used widely for drug
delivery such as liposomes [1–3], microspheres [4, 5], poly-
meric shells, etc. [6]. The drug was loaded on or into these
nanoscaled materials by many kinds of mechanisms, such
as embedding, surface absorption, hydrogen bonding, and
other types of interactions, while the drug loading efficiency
of the current developed nanoscaled drug carriers toward is
still low, normally less than 100 % [7, 8]. Therefore, for effi-
cient drug action, improving the loading efficiency is critical
in drug carrier research. Au nanoparticles can offer signifi-
cant advantages over the these delivery mechanisms in
terms of high stability, high specificity, high drug carrying
capacity, ability for controlled release and the capability to
transport both hydrophilic and hydrophobic molecules [9].
The presence of phospholipids on the mammalian cell
membrane imparts a net negative charge [10], restricting
anionic entities to bind and subsequent transport into
the cell. Despite high uptake efficiency, cationic NPs
tend to be toxic, can elicit immunotoxic and genotoxic
responses in variety of cells [11]. In contrast, anionic
nanoparticles are nontoxic and minimize the protein ad-
sorption on their surfaces, improving the pharmacoki-
netic profile [12]. Using an in vitro tumor model, we
have also shown that the anionic gold NPs can diffuse
faster and would be a better candidate to deliver drugs
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deep inside the tissues. Therefore, strategies to enhance
the intracellular uptake of negatively charged NPs can
aid the drug penetration into the tumor core, circum-
venting the possible cytotoxicity issues.
Due to its excellent biocompatibility and bioadsorbility,
chitosan (CS) has been widely used in biomedical applica-
tions [13]. Also, positive surface charge of CS and its bio-
compatibility enable it to effectively support the cell growth
[14]. In order to get better nanoparticle internalization into
cancer cells, folic acid (FA), a specific tumor tissue-
targeting ligand, expressed in a limited number of normal
tissues but overexpressed in a large number of epithelial
malignancies, was design to conjugate on CS backbone to
form folate-chitosan (FA-CS) nanogels [15].
In order to obtain best antitumor efficacy, sequential
drug release systems based on nanoparticles were used
for delivery two or more different drugs with synergistic
effect [16]. Herein, we demonstrated the use of FA-CS
nanogels for intracellular delivery of anionic gold NPs
(AuCOOH) (Fig. 1), to establish a sequential release
drug delivery system AuNP@FA-CS with loading both
chemo-drug and bio-drug. Temozolomide was chosen as
chemo drug to be loaded in FA-CS nanogels, which has
definite therapeutic efficacy against malignant glioma
[17]. Moreover, in our previous study, we found that
overexpression of miR-218 in glioma cells markedly sup-
presses the motility, invasion, and proliferation of glioma
cells [18, 19], so miR-218 mimics was attached on
AuCOOH (AuCOOH_miR218 mimics) surface as bio
drug. In vivo and in vitro research results revealed that,
the uptake amount of AuCOOH_miR218mimics was en-
hanced using FA-CS nanogel, targeting the receptor-
mediated pathways. Temozolomide was then released by
diffusion due to FA-CS nanogel swelling, followed by
miR-218 mimics was released by place exchange of GSH
in tumor cells. The sequential release of both chemo-
drug and bio-drug exhibited significant synergistic effect
against U87MG glioblastoma cells. Thus, the integration
of biodegradable CS for the intracellular delivery of sur-
face functionalized AuCOOH not only can help in de-
sign systems with high delivery efficacy and excellent
biocompatibility, but also could be a promising sequen-




All chemicals were purchased from Sigma or Fischer Sci-
entific and used as received, unless otherwise mentioned.
Dichloromethane (DCM) as a solvent for chemical synthe-
sis was dried according to the standard procedures. Trans-
mission electron microscopy (TEM) images were acquired
on a JEOL 7C operating at 120 keV. Dynamic light scatter-
ing (DLS) data were measured with a Malvern Zetasizer
Nano ZS. Quantitative analysis of gold nanoparticles
(AuNP) uptake was performed by inductively coupled
plasma mass spectrometry (ICP-MS). Drug release profile
was monitored by High Performance Liquid Chromatog-
raphy (HPLC). Confocal microscopy was used for studying
the endo-lysosome escape of AuCOOH@FA-CS system.
Methods
Preparation of 11-Mercaptoundecanoic acid (MUA)
capped anionic gold nanoparticles (AuCOOH) and
AuCOOH_miR-218 mimics
MUA capped gold nanoparticles (AuCOOH) were pre-
pared from pentane thiol-capped gold NPs (~2 nm core)
via a place exchange reaction. Briefly, 20 mg of pentane
thiol-capped 2 nm gold NPs prepared from Brust-Schiffrin
method [20] and 80 mg of 11-Mercaptoundecanoic acid
were weighed in two separate vials and 5 ml dry DCM
was added to each of the vials. Under nitrogen atmos-
phere, MUA solution was added dropwise to the gold NPs
solution and stirred for 2 days. The black precipitation of
Fig. 1 Schematic of drug design and drug release schedule
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AuCOOH was further washed with Hexane/DCM twice
to remove free ligands, dried under reduced pressure and
solubilized in distilled water. After 2 days of dialysis, the
NPs were lyophilized and redissolved in MilliQ water.
For synthesis of AuCOOH_miR-218 mimics, 20 mg of
pentane thiol-capped 2 nm gold NPs, 20 mg miR-218
mimics (with thiol group), and 60 mg of MUA were
weighed in three separate vials and 5 ml dry DCM was
added to each of the vials. Following protocol was the
same as AuCOOH preparation. Under nitrogen atmos-
phere, MUA solution and miR-218 mimics solution were
added dropwise to the gold NPs solution and stirred for
2 days. The black precipitation of AuCOOH_miR-218
mimics was further dialysis for 2 days to remove free li-
gands, then NPs were lyophilized and redissolved in
MilliQ water.
Preparation of AuCOOH and AuCOOH_miR-218 mimics
encapsulated CS nanogels (AuCOOH@CS and
AuCOOH_miR-218 mimics@CS) and FA decorated CS
nanogels (AuCOOH@FACS and AuCOOH_miR-218
mimics@FACS)
CS nanogels were prepared based on the ionic gelation
of CS with sodium tripolyphosphate (TPP) anions as de-
scribed by Janes et al. [21]. Briefly, CS was dissolved in
acetic aqueous solution (1 % v/v) at concentration of
1.5 mg/mL and was brought to pH 5.0 by dropwise
addition of NaOH (1 M). TPP solution (0.6 mg/mL) was
then dropwise added to the CS solution and stirred for
10 min to get a solution exhibiting an iridescent white
color. The solution was further sonicated to disperse the
nanogels formed.
FA conjugated CS nanogels (FACS) were prepared as re-
ported in by Dubé et al. [22]. Briefly, a solution of 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(EDC) and FA in anhydrous dimethyl sulfoxide (DMSO)
was prepared and stirred at room temperature until FA
was well dissolved (1 h). It was then added to a solution of
1 % (w/v) CS in acetate buffer (pH 4.7). The resulting mix-
ture was stirred at room temperature in the dark for 16 h.
It was brought to pH 9.0 by drop wise addition of diluted
aqueous NaOH and dialyzed first against phosphate buffer
pH 7.4 for 3 days and then against water for 3 days. The
nanogels were formed by addition of TPP.
To each nanogel solution (2.5 ml) AuCOOH solution
(11.375 μM, 1 ml) was dropwise added to the solution to
get AuCOOH@CS and AuCOOH@FACS. Same proced-
ure was used to form AuCOOH_miR-218 mimics@CS
and AuCOOH_miR-218 mimics@FACS. After nanopar-
ticle encapsulation of CS and FACS, nanogels were
immersed in free Temozolomide solution (2 mg/ml,
1 ml) to load chemo-drug in CS nanogels. UV spectrum
was conducted to determine the concentration of free au
nanoparticles in the solution, and the loading efficiency
of AuNP could be calculated.
Characterization of nanogels
Morphologies of AuCOOH, AuCOOH_miR-218 mimics,
AuCOOH_miR-218 mimics @CS and AuCOOH_miR-
218 mimics@FACS were studied by TEM, JEOL 7C de-
vice at 120 kV. Samples were prepared by dilution of the
nanoparticles and nanogels in water, placement of a drop
on a copper grid carrying a 20 nm thick carbon film
(CF-300-Cu, Electron Microscopy Sciences), and dry-
ing for 1 h. Size distribution was determined by DLS
(Malvern Zetasizer Nano ZS). Each experiment was
done in triplicate.
Stability of nanoparticles and nanogels in phosphate
buffered saline (PBS) and medium with serum were in-
vestigated by DLS. Size of AuCOOH_miR-218 mimics in
comparison to fresh made AuCOOH NPs (ΔHydration
diameter > 10 nm), AuCOOH_miR-218 mimics@CS and
AuCOOH_miR-218 mimics@FACS with fresh made
ones (ΔHydration diameter > 100 nm) were regarded as
evidence of aggregation. Each experiment was done in
triplicate.
Temozolomide release from AuCOOH_miR-218
mimics@FACS nanogel was monitored by HPLC. Equal
amounts of AuCOOH_miR-218 mimics@FACS nanogel
(1 mg/mL) was dispersed in 10 mL PBS. Each sample was
centrifuged (15000 rpm/min) at different time points and
supernatant was filtered with a centrifugal filter (molecu-
lar weight cut off: 30 000 Da, Millipore). The NPs were
dried and redispersed in deionized water. Chromatogram
condition: ZORBAX ODS 5 μm (4.6 mm * 150 mm) as
stationary phase, Methanol: glacial acetic acid solution
(5 %) (10:90) as mobile phase, flow rate at 1 ml/min, col-
umn temperature at 35 °C and detected wavelength of
316 nm. Each experiment was done in triplicate.
We also examined the drug release kinetics in the
cells. Cells were seeded at initial densities of 5 × 104
cells/mL (2 ml culture media per dish) in dishes and in-
cubated for 24 h, and changed the medium with
AuCOOH_miR-218 mimics@FACS nanogel (2 ml). Dif-
ferent feeding time interval was adopted, as specified in
individual experimental results. Quantitative intracellular
Temozolomide release experiment was conducted fol-
lowing our previous method [23]. Each experiment was
done in triplicate.
In order to confirm the synergistic effect of miR-218
mimics and Temozolomide, 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) assay was con-
ducted to evaluate cell viability after treatment. We first
confirmed the IC50 of Temozolomide, then chose the
concentration at which cell viability was about 75 % to
carry out the following experiment in vitro and in vivo.
U87MG glioblastoma cells (50000 cell/well) seeded in
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96-well plate and culture for 24 h to adhere the bottom
of plate. Temozolomide were diluted in culture medium
to obtain the desired concentrations (100 μM, 50 μM,
10 μM, 1 μM, 100 nM, 10 nM, 1 nM). After 72 h of cul-
ture time, discarded the culture medium in each well.
Then cells we separately treated with 0.1 mL of Temozo-
lomide (at concentration determined by IC50) and Tem-
ozolomide +miR-218 mimics medium solutions. After
72 h incubation, the culture medium was then removed
and replaced with 100 μL of the new culture medium
containing 10 % MTT reagent. The cells were then incu-
bated for 4 h at 37 °C to allow the formazan dye to form.
The culture medium in each well was then removed,
and DMSO (200 μL/well) was added for an additional
30 min of incubation. The quantification determining
cell viability was performed using optical absorbance
(490 nm) and an ELISA plate reader. Also, synergistic ef-
fects of miR-218 mimics on different concentration of
Temozolomide were also investigated by MTT assay.
The data was expressed as a percentage of control. Each
experiment was done in 5 times.
Cell culture
U87MG glioblastoma cells grown in FA free medium
(positive control cell line with overexpression of folate)
were obtained from Department of immonology, Fourth
military medical university, China and cultured in
DMEM, no FA medium (Sigma, D2429) supplemented
with 10 % fetal bovine serum and 1 % antibiotics. A549
cells as negative control cell line (without folate recep-
tor) (human lung carcinoma) were purchased from the
American Type Culture Collection and were grown in
Ham“s F-12 K Kaighn’s modified medium (Invitrogen,
#21127-022) supplemented with 10 % fetal bovine serum
and 1 % antibiotics. The cells were maintained at 37 °C
in a humidified atmosphere of 5 % CO2 and subcultured
once every four days.
Western blot analysis of folate receptor type α (FR-α)
The expression of FR-α in U87MG and A549 cells were
analyzed by Western blot [24]. A549 lacks folate recep-
tor on the cell surface and used as negative control.
U87MG and A549 were grown in T-75 flasks, washed
with ice-cold PBS, and cells were lysed using Ripa buffer
(50 mM Tris–HCl pH 7.4, 150 mM NaCl, 10 % Glycerol,
0.1 % SDS, 1 % Triton X-100, 0.5 % deoxycholate) in
presence of protease inhibitor cocktail (Sigma, #P8340)
for 10 min on ice. The lysed cell solution was further
centrifuged for 15 min at 4 °C and the supernatant was
collected. Total protein concentration was determined
using the BCA kit (Pierce, Socochim, Switzerland) ac-
cording to the manufacturer’s instructions. Protein sam-
ples (60 μg) were separated on a 10 % denaturing
polyacrylamide gel in absence of dithiothreitol (DTT)
treatments prior to loading and followed by electrophor-
etic transfer to polyvinylidene difluoride (PVDF) mem-
brane (Millipore, # IPVH00010). Membranes were
blocked with 5 % (w/v) nonfat dry milk in TTBS contain-
ing 0.001 % (v/v) Tween-20 for 1 h at room temperature.
Membranes were then incubated overnight at 4 °C with
anti-FR antibody (F5753, US biological), diluted 1:500 in
5 % (w/v) nonfat dry milk in TTBS. After several washes,
the blots were incubated with secondary antimouse anti-
body linked to horseradish peroxidase (NA931V, GE
Healthcare) for 1 h and proteins were further visualized
using chemiluminescence. The membranes were further
stripped and incubated with antibody against β-actin
(Sigma, A-1978) as loading control.
Cell viability assay of nanoparticles and nanogels
U87MG cells were seeded in a 96-well plate at a density
~15,000 cells/well 24 h prior to the experiment. Next
day, the old media was replaced by different concentra-
tions of AuCOOH, CS, FACS, AuCOOH@CS and
AuCOOH@FACS in serum containing media, and the
cells were further incubated for 24 h at 37 °C in a hu-
midified atmosphere of 5 % CO2. The cells were washed
with PBS three times and 10 % alamar blue in serum
containing media was added to each well and further in-
cubated at 37 °C for 4 h. The cell viability was then de-
termined by measuring the fluorescence intensity at
590 nm using a SpectraMax M5 microplate spectropho-
tometer. Viability (%) of NP-treated cells was calculated
taking untreated cells as 100 % viable. Each experiment
was done in triplicate. All datas were analyzed by one-
way ANOVA statistical analysis with Bonferroni’s Mul-
tiple Comparison Test (Graphpad Prism 5.01 software)
to determine the differences between groups. Significant
differences was judged by P < 0.05.
ICP- MS measurements
The amounts of Au uptake were measured on a Perkin-
Elmer Elan 6100 mass spectrometer. Each sample was
measured in triplicate. U87MG and A549 cells were seeded
in 24 well plates at 30,000 cells in 0.5 mL medium 24 h
prior to the experiment. Next day, the cells were washed
with PBS and incubated with AuCOOH miR-218 mimics,
AuCOOH_miR-218 mimics@CS and AuCOOH_miR-218
mimics@FACS (150nM Gold nanoparticles in chitosan) for
6 h cells were washed three times with PBS and lysed. Cell
lysate was digested with 0.5 mL aqua regia for 4 h. After di-
gestion, each sample was diluted into 10 mL de-ionized
water, and subjected to ICP-MS analysis. Cellular uptake
experiments with each gold nanoparticle were repeated
three times, and each replicate was measured five times by
ICP-MS. All of the data are reported as the means ± S.D.
Comparisons were performed with a one-way analysis of
variance (ANOVA) followed by Bonferroni’s multiple
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comparison tests using GraphPad Prism 5.01 software. Sig-
nificance was defined as P < 0.001 (**).
In vivo targeting therapeutic efficacy of nanoparticles and
nanogels
All animal studies were conducted under a protocol ap-
proved by National Institute of Biological Science and
Animal Care Research Advisory Committee of Fourth
Military Medical University. All experiments involving
mice conducted following the guidelines of the Animal
Research Ethics Board of Fourth Military Medical Uni-
versity. Female BALB/C nude mice (6-8 weeks) were
purchased from Hunan SJA Laboratory Animal Co., Ltd.
U87MG cells (5 × 106 cells, total volume 0.1 mL) were
injected into mice leg subcutaneously. All animals were
monitored for activity, physical condition, body weight,
and tumor growth. The animals bearing human cancer
xenografts were randomly divided into 9 treatment
groups (5 mice/group). Drug loaded nanoparticles,
nanogels and free drugs dissolved in saline were admin-
istered by tail intravenous (iv) injection every 3 days at
Temozolomide doses of 10 mg/kg for 3 weeks.
In order to substantiate tumor-specific targeting from
passive accumulation of AuCOOH and provide sufficient
evidence for receptor-specific targeting of AuCOOH_miR-
218 mimics@FACS, in-vivo quantification of NPs was de-
termined by ICP-MS analysis in four treatment groups
(AuCOOH, AuCOOH_miR-218 mimics, AuCOOH_miR-
218 mimics@CS and AuCOOH_miR-218 mimics@FACS)
in tumors 24 h after injection to allow for sufficient time
for the onset of EPR effect. After 24 h, cancerous mice will
be sacrificed for the collection of the tumors. Weigh
known amount of tumor tissue and digest it with nitric
acid: perchloric acid (3:1) (30 ml: 10 ml) with heating and
stirring at 200 °C till the volume reaches 5 ml then
complete with distilled water till 10 or 15 ml. Measure the
gold with ICP-MS. Each experiment was done in triplicate.
All of the data are reported as the means ± S.D. Compari-
sons were performed with a one-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple comparison
tests using GraphPad Prism 5.01 software. Significance was
defined as P < 0.05 (*).
Results and discussion
The DLS size distribution and zeta potential of the
AuCOOH_miR-218 mimics@CS and AuCOOH_miR-
218 mimics@FACS nanogels is showed that the nanogels
are well dispersed in water, PBS buffer and cell culture
medium with 10 % FBS (Additional file 1: Table S1). The
average particle size of AuCOOH_miR-218 mimics@-
FACS nanogels in H2O is about 100 nm with a narrow
size distribution. And the zeta potential was also deter-
mined and shown as +10 mv.
By TEM measurement, the size of AuCOOH_miR-218
mimics@CS and AuCOOH_miR-218 mimics@FACS
nanogels with spherical morphology is about 100 nm
(Fig. 2). The nanoparticles were encapsulated in nano-
gels. This result suggests that gold nanoparticles were
involved in the formation of empty nanogels through the
directed growth of FA-CS or Chitosan molecules on
negatively charged gold nanoparticles. The positively
charged FA-CS or Chitosan are electrostatically adsorbed
and aggregated on gold nanoparticles.
Stability of AuCOOH_miR-218 mimics NPs, AuCOOH_-
miR-218 mimics@CS, and AuCOOH_miR-218 mimics@-
FACS nanogels were investigated by incubating samples in
H2O, PBS and medium with serum for 24 h (Additional
file 1: Figure S1). Size distribution by DLS in comparison
to fresh made AuCOOH NPs (ΔHydration diameter >
10 nm), nanogels (ΔHydration diameter > 100 nm) was
regarded as evidence of aggregation. The size increase of
AuCOOH_miR-218 mimics NPs in three mediums was
found no more than 10 nm, indicating that AuCOOH_-
miR-218 mimics NPs could be stable existing in H2O, PBS
and medium with serum without aggregation. Moreover,
the size distribution of nanogels was also revealing no
Fig. 2 Morphology study of AuCOOH_miR-218 mimics@CS,
AuCOOH_miR-218 mimics@FACS nanogels by TEM. Lyophilized
nanogel powder was redispersed in water by sonication at room
temperature. TEM images were recorded with 120 kV. The dispersion
was placed on a copper grid and air dried before taking the images
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aggregation in this three mediums, due to ΔHydration
diameter of all samples were lower than 100 nm. The sta-
bility test results could confirm that both NPs and nano-
gels could be stable in H2O, PBS, and medium with
serum.
The release behavior of Temozolomide in AuCOOH_-
miR-218 mimics@FACS nanogels was investigated in
PBS (pH 7.4, at 37 °C) and in cytoplasm of U87MG cells.
UV absorption spectra were taken from the supernatant
to measure the amount of Temozolomide released at
certain time intervals. Figure 3 plotted cumulative re-
lease profiles of Temozolomide in PBS (a) and cytoplasm
(b). In Fig. 3a, after an initial quick rise in the amount of
Temozolomide released at 36 h, an obvious plateau ap-
peared in the profile and lasted until 48 h. In the cyto-
plasm, release characteristics of Temozolomide have
similar trend with that in PBS, however, Temozolomide
present quicker release (about 24 h to reach the plateau)
(Fig. 3b).
Based on our previous study on miR-218, we found that
overexpressing of miR-218 could inhibit the growth of gli-
oma. So in our study, we investigated the synergetic effects
of Temozolomide and miR-218 mimics in U87MG cells
by MTT assay. First, we investigated the IC50 of Temozo-
lomide on U87MG cells, which is 6.166 μM. We chose a
proper concentration of 1 μM to carry out the following
experiment, under which the cell viability is about 75 %
(Fig. 4a). As shown in Fig. 4b-c, in U87MG cells, cytotox-
icity of Temozolomide was significantly potentiated by
miR-218 mimics cotreatment. Potentiation of Temozolo-
mide cytotoxicity was most pronounced at 1 μM concen-
tration where caused a double reduction of the cell
viability.
Folate receptor-mediated drug/gene delivery consti-
tutes a useful targeting strategy due to its upregulation
in many human tumors including Glioma. To confirm
the presence of folate receptor on the cell surface we
have performed western blotting of two cell lines:
U87MG and A549. U87MG cells are known to express
folate receptor on their surface whereas A549 is known
to be folate-deficient. As shown in Additional file 1:
Figure S2, High level of FRα was observed in U87MG
cells compared to A549 cells. Therefore, these cells pro-
vide a direct platform to investigate the folate receptor-
mediated uptake of AuCOOH encapsulated nanogels.
We further quantified the toxicity of nanoparticles and
nanogels in U87MG cell line by MTT assay (Additional
file 1: Figure S3 and Table S2). Cytotoxic effects were
not observed in U87MG cells incubated with nanoparti-
cles and nanogels alone at high concentration. The lack
of significant growth inhibition by the nanoparticles and
nanogels indicated that this drug delivery system has
well biocompatibility.
Next, we have performed the intracellular uptake of
nanoparticles and nanogels in both U87MG and A549 cells
(Fig. 5). In case of AuCOOH_miR-218 mimics@CS, the
intracellular gold amount was significantly increased in
both U87MG and A549 cells compared to AuCOOH_miR-
218 mimics which showed very low uptake. Therefore,
encapsulation of AuCOOH_miR-218 mimics in CS in-
creased its intracellular transport. Moreover, the uptake of
AuCOOH_miR-218 mimics@FACS in U87MG cells (folate
positive) was significantly higher than that in A549 cells
(folate negative). A similar uptake profile was observed for
AuCOOH_miR-218 mimics@CS and AuCOOH_miR-218
mimics@FACS in A549 cells in contrast to U87MG cells,
confirming that the presence of folic acid does not improve
the uptake behavior in folate receptor-deficient cells. These
results indicate that CS can be an effective delivery vehicle
for negatively charged gold nanoparticles and the uptake
can be further controlled via specific cell surface receptors.
Fig. 3 Drug release profile of AuCOOH_miR-218 mimics@FACS_
Temozolomide in PBS (a) and cytoplasm (b). Mean comparisons
were made by analysis of variance and protected least significant
difference. Contrasts were considered significant at P < 0.05. Data
were reported as means ± standard errors. Sigmoidal fittings were
performed by Graphpad Prism 5.01 software
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Based on the results in vitro above, we evaluated the
antitumour efficacy of AuCOOH_miR-218 mimics@-
FACS_Temozolomide in xenografts mouse model by i.v.
injection. It significantly delayed subcutaneous U87MG
tumor growth as demonstrated by tumor weight at a
dose of 10 mg/kg every three days i.v. injection (Fig. 6a).
We also tested the effect of other control treatment
groups used at the same dose; they also delayed tumor
growth at different levels. Delaying effect of tumor
growth was primarily due to following factors, targeted
delivery of nanogels by FA, synergistical effects of miR-
218 mimics and Temozolomide. After outer miR-218
mimics and Temozolomide cotreatment, the average
tumor size was less than 1/4 that in the saline control
group. Tumor inhibitory rate of AuCOOH_miR-218
mimics@CS_Temozolomide treatment group was one
step further enhanced; tumor size of this group was
smaller than 1/20 when compared with saline control
group. At the end point of the study with AuCOOH_-
miR-218 mimics@FACS_Temozolomide, tumor weight
decreased by 1/40 (Fig. 6a and d). On the other hand,
changes on body weights were also investigated to evalu-
ate safety of AuCOOH_miR-218 mimics@CS_Temozo-
lomide. No significant decreases of the body weights
were observed in all tumor-bearing mice as compared
with saline control from 4 weeks after initial administra-
tion (Fig. 6b), however, free drug administration groups
exhibited delayed weight growth of mice. These results
indicated that the AuCOOH_miR-218 mimics@FAC-
S_Temozolomide treatment at 10 mg/kg exhibited re-
markable anticancer effect and did not lead to marked
toxicity in experimental mice.
Quantification of Au uptake was also investigated in
tumor site by ICP-MS. Figure 6c showed that, only about
15 % of AuCOOH_miR-218 mimics accumulated in
tumor site due to EPR effect, while nearly 95 % of
AuCOOH_miR-218 mimics@FACS_Temozolomide was
Fig. 4 MTT assay was conducted to evaluate cell viability after treatment. a IC50 value was determined by various concentrations of Temozolomide. b Cell
viability of Temozolomide with or without miR-218 to investigate the synergistic effect. c Cell viability of Temozolomide at different concentrations
with miR-218 to investigate the synergistic effect. All data was presented by mean ± SD of experiments done in triplicate wells. Contrasts were
considered significant at P < 0.05. Sigmoidal fittings were performed by Graphpad Prism 5.01 software
Fig. 5 Quantification of the amount of AuCOOH miR-218 mimics,
AuCOOH_miR-218 mimics@CS and AuCOOH_miR-218 mimics@FACS
present in U87MG and A549 cells. Samples were analysed by ICP-MS
to determine the amount of gold in both U87MG and A549 cells
after 6 h incubation with 150nM of three particles. Cellular uptake
experiments with each gold nanoparticle were repeated three times,
and each replicate was measured five times by ICP-MS. Error bars
represent standard deviations of these measurements. Comparisons
were performed with a one-way analysis of variance (ANOVA)
followed by Bonferroni’s multiple comparison tests using GraphPad
Prism 5.01 software. Significance was defined as P < 0.001 (**)
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found in tumor, providing sufficient evidence for receptor-
specific targeting by FA.
Conclusion
Tumor-homing and sequential drug delivery system
AuCOOH@FACS nanogels for sequential delivery of miR-
218 mimics (as a bio-drug) and Temozolomide (as a
chemo-drug) was established by using of CS and FA-CS
nanogels for intracellular negative gold nanoparticles deliv-
ery. Significantly enhanced intracellular uptake of nega-
tively charged particle is enhanced to a greater extent.
Antitumor efficacy was achieved due to targeting function
and sequential release of chemo-agents and bio-drugs.
Such nanoparticle drug system was also found to largely
Fig. 6 Antitumor effect of nanoparticles and nanogels on nude mice bearing U87MG cells subcutaneously were studied in vivo. Values of tumor
weight (a) and body weight (b) changes are expressed as Mean ± SD (g, n = 5). Quantification of Au in tumor site was investigated by ICP-MS (c).
The nude mice were administered via i.v. injection every 3 days. All of the data are reported as the means ± S.D. Macroscopic images of resected
tumors at the conclusion of the experiment (d).
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reduced system toxicity. This system offers an efficient ap-
proach to cancer therapy and holds significant potential to
improve the treatment of cancer in the future.
Additional file
Additional file 1: Supplementary figures. (DOCX 524 kb)
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